QPS is Supporting the Fight Against SARS-COV-2
We are currently in the midst of the greatest global health crisis in decades: the COVID-19 pandemic. As this novel coronavirus affects communities around the world, there is an increasingly urgent demand for available and accurate COVID-19 testing services, effective COVID-19 drug therapies, and a COVID-19 vaccine. With its proven quality standards, technical expertise, turnkey laboratories, and decades of experience, QPS is well prepared to support your novel coronavirus or COVID-19-related project.
QPS is Open for Business
QPS remains open and fully operational, supporting preclinical and clinical novel coronavirus drug therapy and vaccine development, as well as providing a range of testing capabilities. With multiple phase I clinical research sites around the world, and over 600 Phase I beds, QPS is also well positioned to safely fast-track first-in-man and Phase I/II studies for compounds in development to combat the novel coronavirus.
Links to Relevant Documents
Contatct QPS Today to Discuss Your Coronavirus Related Projects
Decades of Experience
With multiple Phase I clinical research sites around the world, and over 600 Phase I beds, QPS is also well positioned to fast-track first-in-man and Phase I/II safety studies for compounds in development to combat the novel coronavirus. Furthermore, as a full service CRO QPS has all clinical research capabilities as well as efficient access to specialized sites and experienced investigators with the capability to run COVID-19 patient trials in EU, US and Asia.
QPS has decades of experience assisting pharmaceutical companies slow the progress of viral outbreaks, and we are committed to supporting the life sciences community in fighting COVID-19. Due to the catastrophic reach of this pandemic, a scientific breakthrough is direly needed, and our team is ready to move your clinical trials, serological assays, and vaccine and drug development programs toward a regulatory submission.
Please use the form below to submit your request for preclinical or clinical drug development and testing services related to the novel coronavirus or COVID-19.
Contact Us Today!
More Information About COVID-19
The spread of COVID-19 is impacting every facet of the pharmaceutical industry, including planned and ongoing clinical trials. Recognizing that the coronavirus presents challenges to protocol-specified procedures, the Food and Drug Administration (FDA) has published guidelines regarding the conduct of clinical trials during this unprecedented time. To learn more about these guidelines, please visit our page Clinical Trials: Coronavirus Impact and FDA Guidelines.
Today, the FDA issued a new video resource explaining the different categories of tests in the fight against COVID-19: diagnostic tests and antibody tests. As the video explains, diagnostic tests can tell if the tested person currently is infected. Antibody or serology tests detect if the person’s blood contains antibodies to coronavirus. The body produces antibodies when one becomes infected by the virus, and they help the immune system fight off the infection. If an antibody test finds antibodies in the blood, it likely means the person has been previously infected with the virus. Antibody tests do not detect whether a person is currently infected and should not be used to diagnose a current COVID-19 infection. The results from antibody tests can help us better understand questions about exposure to COVID-19.
